JJJulia Jiménez-López

Julia Jiménez-López

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julia Jiménez-López has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Consolación Melguizo

    Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain

    4 shared publications
  • Jose Prados

    Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain

    4 shared publications
  • Laura Cabeza

    Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain

    4 shared publications
  • Raul Ortiz

    Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain

    3 shared publications
  • Francisco Javier Cejudo

    Instituto de Bioquímica Vegetal y Fotosíntesis, Universidad de Sevilla and CSIC, Avda. Américo Vespucio 49, 41092-Sevilla, Spain

    2 shared publications
  • Gloria Perazzoli

    Institute of Biopathology and Regenerative Medicine (IBIM9090325ER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain; Biosanitary Institute of Granada (ibs.GRANADA), SAS-University of Granada, 18014 Granada, Spain

    2 shared publications

Latest Publications

  • Open Access

    2-Cys peroxiredoxins facilitate phosphatidylglycerol unsaturation and contribute to PSII recovery from high-light photoinhibition

    by M. Luisa Hernández, Julia Jiménez-López, Fernando Rodríguez-Marín, Valle Ojeda, Alicia Gálvez-Ramírez, Francisco J. Cejudo, Juan M. Pérez-Ruiz

    The level of fatty acid unsaturation of chloroplast lipids is a key determinant of plant acclimation to different environmental stresses. Though the enzymes catalysing fatty acid desaturation are well known, the regulatory mechanisms linking their activity to environmental signals remain poorly understood. In this work, we have addressed the role of chloroplast 2-Cys peroxiredoxins (Prxs), thiol peroxidases that play a central role in redox regulation, in ω-3 fatty acid desaturation in lipids of the organelle, and their contribution to plant acclimation to environmental stress. Genetic and lipidomic analyses of Arabidopsis ( Arabidopsis thaliana ) mutants lacking 2-Cys Prxs and/or the chloroplast ω-3 fatty acid desaturases FAD7 and FAD8 revealed that 2-Cys Prxs are required for the efficient synthesis of trienoic fatty acids in thylakoid membrane lipids, particularly in phosphatidylglycerol (PG). Different approaches show the in vivo interaction of 2-Cys Prxs with FAD7 and FAD8. However, no redox changes of these desaturases were observed regardless the contents of 2-Cys Prxs, thus indicating a regulatory mechanism independent of the classical cysteine-based redox switch. The combined absence of 2-Cys Prxs and chloroplast ω-3 desaturases severely compromised recovery from high-light photoinhibition, indicating that both systems act concertedly to maintain photosystem II (PSII) function under stress. Together, our results uncover a novel role of 2-Cys Prxs controlling the level of chloroplast PG cis -unsaturation and raise the possibility that the chaperone/scaffold activity of these enzymes links membrane lipid remodelling to photosynthetic stress response.

  • Open Access

    2-Cys peroxiredoxins contribute to thylakoid lipid unsaturation by affecting ω-3 fatty acid desaturase 8

    by María Luisa Hernández, Julia Jiménez-López, Francisco Javier Cejudo, Juan Manuel Pérez-Ruiz

    Fatty acid unsaturation levels affect chloroplast function and plant acclimation to environmental cues. However, the regulatory mechanism(s) controlling fatty acid unsaturation in thylakoid lipids is poorly understood. Here, we have investigated the connection between chloroplast redox homeostasis and lipid metabolism by focusing on 2-Cys peroxiredoxins (Prxs), which play a central role in balancing the redox state within the organelle. The chloroplast redox network relies on NADPH-dependent thioredoxin reductase C (NTRC), which controls the redox balance of 2-Cys Prxs to maintain the reductive activity of redox-regulated enzymes. Our results show that Arabidopsis (Arabidopsis thaliana) mutants deficient in 2-Cys Prxs contain decreased levels of trienoic fatty acids, mainly in chloroplast lipids, indicating that these enzymes contribute to thylakoid membrane lipids unsaturation. This function of 2-Cys Prxs is independent of NTRC, the main reductant of these enzymes, hence 2-Cys Prxs operates beyond the classic chloroplast regulatory redox system. Moreover, the effect of 2-Cys Prxs on lipid metabolism is primarily exerted through the prokaryotic pathway of glycerolipid biosynthesis and fatty acid desaturase 8 (FAD8). While 2-Cys Prxs and FAD8 interact in leaf membranes as components of a large protein complex, the levels of FAD8 were markedly decreased when FAD8 is overexpressed in 2-Cys Prxs-deficient mutant backgrounds. These findings reveal a function for 2-Cys Prxs, possibly acting as a scaffold protein, affecting the unsaturation degree of chloroplast membranes.


  • Open Access

    Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer

    by Laura Cabeza, Mazen M. El-Hammadi, Raul Ortiz, Maria D. Cayero-Otero, Julia Jiménez-López, Gloria Perazzoli, Lucia Martin-Banderas, Jose M. Baeyens, Consolación Melguizo, Jose Prados

    Introduction: Paclitaxel (PTX) is a cornerstone in the treatment of breast cancer, the most common type of cancer in women. However, this drug has serious limitations, including lack of tissue-specificity, poor water solubility, and the development of drug resistance. The transport of PTX in a polymeric nanoformulation could overcome these limitations. Methods: In this study, PLGA-PTX nanoparticles (NPs) were assayed in breast cancer cell lines, breast cancer stem cells (CSCs) and multicellular tumor spheroids (MTSs) analyzing cell cycle, cell uptake (Nile Red-NR-) and α-tubulin expression. In addition, PLGA-PTX NPs were tested in vivo using C57BL/6 mice, including a biodistribution assay. Results: PTX-PLGA NPs induced a significant decrease in the PTX IC50 of cancer cell lines (1.31 and 3.03-fold reduction in MDA-MB-231 and E0771 cells, respectively) and CSCs. In addition, MTSs treated with PTX-PLGA exhibited a more disorganized surface and significantly higher cell death rates compared to free PTX (27.9% and 16.3% less in MTSs from MCF-7 and E0771, respectively). PTX-PLGA nanoformulation preserved PTX’s mechanism of action and increased its cell internalization. Interestingly, PTX-PLGA NPs not only reduced the tumor volume of treated mice but also increased the antineoplastic drug accumulation in their lungs, liver, and spleen. In addition, mice treated with PTX-loaded NPs showed blood parameters similar to the control mice, in contrast with free PTX. Conclusion: These results suggest that our PTX-PLGA NPs could be a suitable strategy for breast cancer therapy, improving antitumor drug efficiency and reducing systemic toxicity without altering its mechanism of action.


  • Open Access

    Evaluation of Novel Doxorubicin-Loaded Magnetic Wax Nanocomposite Vehicles as Cancer Combinatorial Therapy Agents

    by Julia Jiménez-López, Lorena García-Hevia, Consolación Melguizo, Jose Prados, Manuel Bañobre-López, Juan Gallo

    The development of nanotechnology-based solutions for cancer at a preclinical level advances at an astounding pace. So far, clinical translation of these new developments has not been able to keep the pace due to a range of different reasons. One of them is the mismatch between in vitro and in vivo results coming from the expected difference in complexity. To overcome this problem, extensive characterisation using advanced in vitro models can lead to stronger preliminary data to face in vivo tests. Here, a comprehensive in vitro validation of a combinatorial therapy nanoformulation against solid tumours is presented. The information extracted from the different in vitro models highlights the importance of advanced 3D models to fully understand the potential of this type of complex drugs.


  • A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer

    by Julia Jiménez-López, Mazen M. El-Hammadi, Raul Ortiz, Maria D. Cayero-Otero, Laura Cabeza, Gloria Perazzoli, Lucia Martin-Banderas, Jose M. Baeyens, Jose Prados, Consolación Melguizo


  • Nanomedical Platform for Drug Delivery in Cancer

    by Raul Ortiz, Laura Cabeza, Maria C. Leiva, Julia Jimenez-Lopez, Consolacion Melguizo, Jose Prados

    Abstract: Cancer is a disease in which cells show an atypical behavior and begin to divide abnormally without control. Furthermore, these cells can spread to other tissues and result in the development of new tumors. It is very difficult to find a treatment that discriminates between tumor cells and healthy cells because cancerous cells are from the person who has the disease and they are not an external and foreign pathogen easily recognizable by the immune system. Thus, the treatments that currently exist for cancer disease are quite nonspecific and they also attack healthy cells, producing a highly specific toxicity and, therefore, severe side effects. Moreover, drugs used in cancer treatment are metabolized and eliminated rapidly from the body, the administration of large amounts of drugs necessarily leading to the increase of the unspecific toxicity produced by the drug. Nanotechnology may provide the solution to these problems by the synthesis of nanoplatforms that are able to make these drugs more specific for tumoral tissues, thus increasing the drug half-life in the body and thereby reducing non-specific toxicity and thus the side effects of the drugs. Some of the strategies employed in the field of nanotechnology against cancer to improve anti-tumor therapy are, for example, overcome by the MDR phenotype, which has some tumor cells (thanks to different materials used in the synthesis of nanoparticles), active targeting against tumor cells (because of its union with different structures that recognize tumor cells) or make the nanoparticles sensitive to certain conditions that allow the release of the drug transported to the tumor site (for example conditions of acidity or alkalinity of the environment). For these reasons, nanotechnology applied to the biomedical sciences has been having a great development in recent years. In this chapter, we review the different therapeutic strategies in the fight against cancer in which nanotechnology can help, describing the materials most widely used in tumor therapy, presenting a great versatility thanks to which nanomedical platforms can be used to overcome the current limitations in the use of free antitumor drugs.


  • Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer

    by Ana R. Rama, Julia Jimenez-Lopez, Laura Cabeza, Cristina Jimenez-Luna, Maria C. Leiva, Gloria Perazzoli, Rosa Hernandez, Inmaculada Zafra, Raul Ortiz, Consolacion Melguizo, et al.

    Colorectal cancer is the third most common type of cancer in both, men and women. The development of metastasis is very frequent, especially in patients with advanced stage, who require intensive chemotherapy that often results in poor response and significant morbidity. The undesirable effects of intensive chemotherapy on normal cells and the development of multidrug resistance are two of the main causes of treatment failure. Recent advances in nanotechnology allow to target cancer cells using cytotoxic drugs without affecting normal cells. Nanocarriers such as liposomes, polymeric nanoparticles and carbon nanotubes, among others, are able to improve drug distribution and bioavailability, cytotoxic concentration in the tumor mass and drug delivery to tumor tissue and, at the same time, reduce side effects. Current research studies are being conducted to develop new biomaterials that improve the characteristics of these nanomolecules. Several preclinical assays have disclosed the efficacy of nanotherapy in colon cancer, although further clinical trials will be necessary to demonstrate its efficacy. This review discusses the current status and the potential advantages of using nanocarrier-based drug delivery systems for colorectal cancer.


  • Open Access

    Biofilm formation-defective mutants inPseudomonas putida

    by Aroa López-Sánchez, Antonio Leal-Morales, Lorena Jiménez-Díaz, Ana I. Platero, Juan Bardallo-Pérez, Alberto Díaz-Romero, Rafael D. Acemel, Juan M. Illán, Julia Jiménez-López, Fernando Govantes

    Out of 8000 candidates from a genetic screening for Pseudomonas putida KT2442 mutants showing defects in biofilm formation, 40 independent mutants with diminished levels of biofilm were analyzed. Most of these mutants carried insertions in genes of the lap cluster, whose products are responsible for synthesis, export and degradation of the adhesin LapA. All mutants in this class were strongly defective in biofilm formation. Mutants in the flagellar regulatory genes fleQ and flhF showed similar defects to that of the lap mutants. On the contrary, transposon insertions in the flagellar structural genes fliP and flgG, that also impair flagellar motility, had a modest defect in biofilm formation. A mutation in gacS, encoding the sensor element of the GacS/GacA two-component system, also had a moderate effect on biofilm formation. Additional insertions targeted genes involved in cell envelope function: PP3222, encoding the permease element of an ABC-type transporter and tolB, encoding the periplasmic component of the Tol-OprL system required for outer membrane stability. Our results underscore the central role of LapA, suggest cross-regulation between motility and adhesion functions and provide insights on the role of cell envelope trafficking and maintenance for biofilm development in P. putida.